2022-04-012023-03-312023-03-31false12492923Zuma Labs Limited2024-02-07iso4217:GBPxbrli:pure124929232022-04-01124929232023-03-31124929232022-04-012023-03-31124929232021-04-01124929232022-03-31124929232021-04-012022-03-3112492923bus:SmallEntities2022-04-012023-03-3112492923bus:AuditExempt-NoAccountantsReport2022-04-012023-03-3112492923bus:FullAccounts2022-04-012023-03-3112492923bus:PrivateLimitedCompanyLtd2022-04-012023-03-3112492923core:WithinOneYear2023-03-3112492923core:AfterOneYear2023-03-3112492923core:WithinOneYear2022-03-3112492923core:AfterOneYear2022-03-3112492923core:ShareCapital2023-03-3112492923core:SharePremium2023-03-3112492923core:RevaluationReserve2023-03-3112492923core:OtherReservesSubtotal2023-03-3112492923core:RetainedEarningsAccumulatedLosses2023-03-3112492923core:ShareCapital2022-03-3112492923core:SharePremium2022-03-3112492923core:RevaluationReserve2022-03-3112492923core:OtherReservesSubtotal2022-03-3112492923core:RetainedEarningsAccumulatedLosses2022-03-3112492923core:LandBuildings2023-03-3112492923core:PlantMachinery2023-03-3112492923core:Vehicles2023-03-3112492923core:FurnitureFittings2023-03-3112492923core:OfficeEquipment2023-03-3112492923core:NetGoodwill2023-03-3112492923core:IntangibleAssetsOtherThanGoodwill2023-03-3112492923core:ListedExchangeTraded2023-03-3112492923core:UnlistedNon-exchangeTraded2023-03-3112492923core:LandBuildings2022-03-3112492923core:PlantMachinery2022-03-3112492923core:Vehicles2022-03-3112492923core:FurnitureFittings2022-03-3112492923core:OfficeEquipment2022-03-3112492923core:NetGoodwill2022-03-3112492923core:IntangibleAssetsOtherThanGoodwill2022-03-3112492923core:ListedExchangeTraded2022-03-3112492923core:UnlistedNon-exchangeTraded2022-03-3112492923core:LandBuildings2022-04-012023-03-3112492923core:PlantMachinery2022-04-012023-03-3112492923core:Vehicles2022-04-012023-03-3112492923core:FurnitureFittings2022-04-012023-03-3112492923core:OfficeEquipment2022-04-012023-03-3112492923core:NetGoodwill2022-04-012023-03-3112492923core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3112492923core:ListedExchangeTraded2022-04-012023-03-3112492923core:UnlistedNon-exchangeTraded2022-04-012023-03-3112492923core:MoreThanFiveYears2022-04-012023-03-3112492923core:Non-currentFinancialInstruments2023-03-3112492923core:Non-currentFinancialInstruments2022-03-3112492923dpl:CostSales2022-04-012023-03-3112492923dpl:DistributionCosts2022-04-012023-03-3112492923core:LandBuildings2022-04-012023-03-3112492923core:PlantMachinery2022-04-012023-03-3112492923core:Vehicles2022-04-012023-03-3112492923core:FurnitureFittings2022-04-012023-03-3112492923core:OfficeEquipment2022-04-012023-03-3112492923dpl:AdministrativeExpenses2022-04-012023-03-3112492923core:NetGoodwill2022-04-012023-03-3112492923core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3112492923dpl:GroupUndertakings2022-04-012023-03-3112492923dpl:ParticipatingInterests2022-04-012023-03-3112492923dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3112492923core:ListedExchangeTraded2022-04-012023-03-3112492923dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3112492923core:UnlistedNon-exchangeTraded2022-04-012023-03-3112492923dpl:CostSales2021-04-012022-03-3112492923dpl:DistributionCosts2021-04-012022-03-3112492923core:LandBuildings2021-04-012022-03-3112492923core:PlantMachinery2021-04-012022-03-3112492923core:Vehicles2021-04-012022-03-3112492923core:FurnitureFittings2021-04-012022-03-3112492923core:OfficeEquipment2021-04-012022-03-3112492923dpl:AdministrativeExpenses2021-04-012022-03-3112492923core:NetGoodwill2021-04-012022-03-3112492923core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3112492923dpl:GroupUndertakings2021-04-012022-03-3112492923dpl:ParticipatingInterests2021-04-012022-03-3112492923dpl:GroupUndertakingscore:ListedExchangeTraded2021-04-012022-03-3112492923core:ListedExchangeTraded2021-04-012022-03-3112492923dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-04-012022-03-3112492923core:UnlistedNon-exchangeTraded2021-04-012022-03-3112492923core:NetGoodwill2023-03-3112492923core:IntangibleAssetsOtherThanGoodwill2023-03-3112492923core:LandBuildings2023-03-3112492923core:PlantMachinery2023-03-3112492923core:Vehicles2023-03-3112492923core:FurnitureFittings2023-03-3112492923core:OfficeEquipment2023-03-3112492923core:AfterOneYear2023-03-3112492923core:WithinOneYear2023-03-3112492923core:ListedExchangeTraded2023-03-3112492923core:UnlistedNon-exchangeTraded2023-03-3112492923core:ShareCapital2023-03-3112492923core:SharePremium2023-03-3112492923core:RevaluationReserve2023-03-3112492923core:OtherReservesSubtotal2023-03-3112492923core:RetainedEarningsAccumulatedLosses2023-03-3112492923core:NetGoodwill2022-03-3112492923core:IntangibleAssetsOtherThanGoodwill2022-03-3112492923core:LandBuildings2022-03-3112492923core:PlantMachinery2022-03-3112492923core:Vehicles2022-03-3112492923core:FurnitureFittings2022-03-3112492923core:OfficeEquipment2022-03-3112492923core:AfterOneYear2022-03-3112492923core:WithinOneYear2022-03-3112492923core:ListedExchangeTraded2022-03-3112492923core:UnlistedNon-exchangeTraded2022-03-3112492923core:ShareCapital2022-03-3112492923core:SharePremium2022-03-3112492923core:RevaluationReserve2022-03-3112492923core:OtherReservesSubtotal2022-03-3112492923core:RetainedEarningsAccumulatedLosses2022-03-3112492923core:NetGoodwill2021-04-0112492923core:IntangibleAssetsOtherThanGoodwill2021-04-0112492923core:LandBuildings2021-04-0112492923core:PlantMachinery2021-04-0112492923core:Vehicles2021-04-0112492923core:FurnitureFittings2021-04-0112492923core:OfficeEquipment2021-04-0112492923core:AfterOneYear2021-04-0112492923core:WithinOneYear2021-04-0112492923core:ListedExchangeTraded2021-04-0112492923core:UnlistedNon-exchangeTraded2021-04-0112492923core:ShareCapital2021-04-0112492923core:SharePremium2021-04-0112492923core:RevaluationReserve2021-04-0112492923core:OtherReservesSubtotal2021-04-0112492923core:RetainedEarningsAccumulatedLosses2021-04-0112492923core:AfterOneYear2022-04-012023-03-3112492923core:WithinOneYear2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:CostValuation2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3112492923core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3112492923core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3112492923core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3112492923core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3112492923core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3112492923bus:Director12022-04-012023-03-3112492923bus:Director22022-04-012023-03-3112492923bus:Director32022-04-012023-03-3112492923bus:Director42022-04-012023-03-31

Zuma Labs Limited

Registered Number
12492923
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2023

Zuma Labs Limited
Company Information
for the year from 1 April 2022 to 31 March 2023

Directors

C Bennett
S W P Bots
O P H Oppetit
T P Simmonds

Registered Address

128 City Road
London
EC1V 2NX

Registered Number

12492923 (England and Wales)
Zuma Labs Limited
Statement of Financial Position
31 March 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Intangible assets94,8826,862
Tangible assets103,3285,019
8,21011,881
Current assets
Debtors11183,585140,649
Cash at bank and on hand61,106262,004
244,691402,653
Creditors amounts falling due within one year12(132,811)(56,917)
Net current assets (liabilities)111,880345,736
Total assets less current liabilities120,090357,617
Net assets120,090357,617
Capital and reserves
Called up share capital12,50012,500
Share premium742,082742,082
Profit and loss account(634,492)(396,965)
Shareholders' funds120,090357,617
The financial statements were approved and authorised for issue by the Board of Directors on 7 February 2024, and are signed on its behalf by:
C Bennett
Director
Registered Company No. 12492923
Zuma Labs Limited
Notes to the Financial Statements
for the year ended 31 March 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006
3.Principal activities
The principal activity of the company in the period under review was that of technological business support service activities.
4.Smallest group in which results are consolidated
Ultimate Controlling Party Ultimate controlling party is Fractal Technologies Limited, a company incorporated in United Kingdom with its registered offices situated at 160 City Road, London, England, EC1V 2NX.
5.Basis of measurement used in financial statements
The financial statements have been prepared under the historical cost convention.
6.Accounting policies
Functional and presentation currency policy
The financial statements are presented in pound sterling (£), which is the company's functional currency, and figures are rounded to the nearest whole pound.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Property, plant and equipment policy
Tangible assets are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Straight line (years)
Office Equipment3
Intangible assets policy
Intangible assets are stated at cost less accumulated amortization and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. Amortization is provided at the following annual rates in order to write off each asset over its estimated useful life. Intellectual property : Straight line over 5 years
Revenue recognition policy
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. The statement of financial position is credited with the value of invoiced sales, as deferred income, which is then amortised to revenue over the period of the contract. At the statement of financial position date, the carrying value of deferred income reflects the total value of invoiced sales which has not yet been recognised as revenue.
Taxation policy
Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date. Tax credits shown on the Income Statement represent tax credits received from HMRC as a result of claims made under HMRC's R&D tax relief schemes
Research and development policy
Revenue expenditure on research and development is written off in the period in which it is incurred. The company makes claims under the SME R&D tax relief scheme. Tax credits arising from claims under the scheme are reflected 'below the line' as a reduction in the Corporation Tax charge or, if loss making, as a Corporation Tax credit. Tax credits receivable from R&D claims are recognised in the reporting period in which the qualifying expenditure is incurred.
Foreign currency translation and operations policy
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each reporting year-end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at the year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.
Leases policy
Rentals paid under operating leases are charged to the Income Statement on a straight line basis over the period of the lease.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
Valuation of financial instruments policy
The Company has chosen to adopt the Sections 11 and 12 of FRS 102 in respect of financial instruments. The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non puttable ordinary shares. Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently,at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out right short term loan not at market rate, the financial asset or liability is measured, initially,at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost. Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Cash and Cash Equivalents : Cash and cash equivalents comprise cash on hand and demand deposits and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk to changes in value.
Going concern
The financial statements have been prepared on a going concern basis. The company incurred losses during the period however the directors were able to attract further investment in the company hence the directors believe the company has sufficient cash resources to meet its obligations, if and when, they become due. They are therefore of the opinion that they should continue to adopt the going concern basis of accounting in preparing the financial statements.
7.Critical estimates and judgements
There are no significant judgements or estimates applied to the numbers contained within these financial statements.
8.Employee information

20232022
Average number of employees during the year44
9.Intangible assets
Other intangible assets consist of capitalised costs in relation to Intellectual property.

Other

Total

££
Cost or valuation
At 01 April 229,9009,900
At 31 March 239,9009,900
Amortisation and impairment
At 01 April 223,0383,038
Charge for year1,9801,980
At 31 March 235,0185,018
Net book value
At 31 March 234,8824,882
At 31 March 226,8626,862
10.Property, plant and equipment

Office Equipment

Total

££
Cost or valuation
At 01 April 226,7796,779
Additions749749
At 31 March 237,5287,528
Depreciation and impairment
At 01 April 221,7601,760
Charge for year2,4402,440
At 31 March 234,2004,200
Net book value
At 31 March 233,3283,328
At 31 March 225,0195,019
11.Debtors

2023

2022

££
Trade debtors / trade receivables70,041-
Other debtors113,544140,549
Called up share capital not paid, current asset-100
Total183,585140,649
12.Creditors within one year

2023

2022

££
Trade creditors / trade payables78,612-
Taxation and social security25,72750,534
Other creditors28,4726,383
Total132,81156,917